Literature DB >> 14158958

PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.

G D HART.   

Abstract

Much can be achieved in the management of and treatment of the complications of metastatic gastrointestinal cancer. Ascites accompanied by identifiable malignant cells frequently can be controlled by intraperitoneal chemotherapy. The symptoms of a deficiency anemia may be relieved by suitable replacement therapy. Radiotherapy may relieve dysphagia. There is no single effective remedy for persistent hiccups; some of the commonly used measures are described. 5-Fluorouracil (5 FU) is the first chemotherapeutic agent found to have a significant effect on gastrointestinal adenocarcinoma. Treatment may be accompanied by severe toxicity and should be administered in hospital by experienced chemotherapists. Radiotherapy may relieve perineal pain, tenesmus, dysphagia and discharge.

Entities:  

Keywords:  ASCITES; DEGLUTITION DISORDERS; FLUOROURACIL; NEOPLASM METASTASIS; NEOPLASM RADIOTHERAPY; RECTAL NEOPLASMS; STOMACH NEOPLASMS; THIO-TEPA

Mesh:

Substances:

Year:  1964        PMID: 14158958      PMCID: PMC1927139     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  2 in total

1.  The primary treatment of adenocarcinoma of the rectum by high voltage roentgen rays (1,000 kv).

Authors:  H HORWITZ; I G WILLIAMS
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1956-11

2.  The spread of rectal cancer and its effect on prognosis.

Authors:  C E DUKES; H J BUSSEY
Journal:  Br J Cancer       Date:  1958-09       Impact factor: 7.640

  2 in total
  2 in total

Review 1.  Multimodality treatment strategies have changed prognosis of peritoneal metastases.

Authors:  Corneliu Lungoci; Aurel Ion Mironiuc; Valentin Muntean; Traian Oniu; Hubert Leebmann; Max Mayr; Pompiliu Piso
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

2.  Curative, Life-Extending, and Palliative Chemotherapy: New Outcomes Need New Names.

Authors:  Alfred I Neugut; Holly G Prigerson
Journal:  Oncologist       Date:  2017-05-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.